These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20065643)

  • 1. European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK.
    Reichert JM; Beck A; Iyer H
    MAbs; 2009; 1(5):394-416. PubMed ID: 20065643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany.
    Reichert JM
    MAbs; 2011; 3(3):223-40. PubMed ID: 21487235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Typical pitfalls in applications for marketing authorization of biotechnological products in Europe.
    Schneider CK; Schäffner-Dallmann G
    Nat Rev Drug Discov; 2008 Nov; 7(11):893-9. PubMed ID: 18974748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
    Scott BJ; Klein AV; Wang J
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical assessment of biosimilar products.
    Chow SC; Liu JP
    J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014).
    Cook G; France G; Holte Ø; Lorenti G; Tainsh D
    PDA J Pharm Sci Technol; 2016; 70(2):163-76. PubMed ID: 26797977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevant issues to biossimilars licensing.
    Peres BS; Padilha G; Quental C
    Rev Bras Epidemiol; 2012 Dec; 15(4):748-60. PubMed ID: 23515771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.
    Combe C; Tredree RL; Schellekens H
    Pharmacotherapy; 2005 Jul; 25(7):954-62. PubMed ID: 16006274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar medicines--new challenges for a new class of medicine.
    Fox A
    J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.
    Beck A; Wurch T; Reichert JM
    MAbs; 2011; 3(2):111-32. PubMed ID: 21441785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical aspects of biosimilarity issues of protein drugs.
    Kálmán-Szekeres Z; Olajos M; Ganzler K
    J Pharm Biomed Anal; 2012 Oct; 69():185-95. PubMed ID: 22633839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Biosimilar' drugs poised to penetrate market.
    Ledford H
    Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
    [No Abstract]   [Full Text] [Related]  

  • 16. Overhauling oversight--European drug legislation.
    Tsang L
    Nat Biotechnol; 2005 Sep; 23(9):1050-3. PubMed ID: 16151389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey.
    Oner ZG; Michel SLJ; Polli JE
    Ann N Y Acad Sci; 2017 Nov; 1407(1):26-38. PubMed ID: 29090833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
    Moorkens E; Vulto AG; Huys I
    MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory considerations in oncologic biosimilar drug development.
    Macdonald JC; Hartman H; Jacobs IA
    MAbs; 2015; 7(4):653-61. PubMed ID: 25961747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union.
    van Aerts LA; De Smet K; Reichmann G; van der Laan JW; Schneider CK
    MAbs; 2014; 6(5):1155-62. PubMed ID: 25517301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.